Search

Author/Creator Letrent, Stephen

1. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014)

Authors:
Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A.
Journal:
Cancer
Issue:
Volume 120:Issue 8(2014)
Page Start:
1145
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014)

Authors:
Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A.
Journal:
Cancer
Issue:
Volume 120:Issue 8(2014)
Page Start:
1145
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. (January 2013)

Authors:
Boyer, Michael; Jänne, Pasi Antero; Mok, Tony; O'Byrne, Kenneth; Paz-Ares, Luis; Ramalingam, Suresh S; Liang, Jane; Taylor, Ian; Campbell, Alicyn; O'Connell, Joseph; Letrent, Stephen; Antic, Vladan
Journal:
Clinical investigation
Issue:
Volume 3:Number 1(2013)
Page Start:
29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. (January 2013)

Authors:
Boyer, Michael; Jänne, Pasi Antero; Mok, Tony; O'Byrne, Kenneth; Paz-Ares, Luis; Ramalingam, Suresh S; Liang, Jane; Taylor, Ian; Campbell, Alicyn; O'Connell, Joseph; Letrent, Stephen; Antic, Vladan
Journal:
Clinical investigation
Issue:
Volume 3:Number 1(2013)
Page Start:
29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search